Feasibility study on validation of DNA cancer biomarkers by IR spectroscopy to guide personalized medical care

In general, establishment of project proposal is directed towards H2020, to SME's Instrument - Phase 1 2014. It includes drafting a detailed business plan, as well a feasibility study to verify technological, practical and economic viability of the clinical validation proposed. The latter includes delineation of the company work package proposal to analyse bottlenecks and to identify how a Phase 2 proposal may contribute to attaining growth or sustainability. Bottlenecks in the ability to increase profitability of the enterprise through innovation shall be detected and analysed during Phase 1 and addressed during Phase 2 to increase the return in investment in innovation activities. Precisely, company plans an innovation strategy development, market study and user involvement for proposed new market applications of existing technologies with the use of FTIR spectroscopy. There is an urgent demand in healthcare for a method to be used in personalized medicine for fast monitoring and online screening of the efficacy of the therapy used in cancer patients. The overall concept and objectives of the EU project is to develop new market applications of existing technologies, FTIR (Fourier transform infrared) microspectroscopy and FEW-FTIR (fiberoptic evanescent wave Fourier transform infrared) spectroscopy in oncology. Currently, company is developing an innovative molecular diagnostic method to monitor DNA band biomarkers in IR (infrared) spectra measured in benign, premalignant and malignant cancerous tissues with the use of the above mentioned prototype technologies. Consequently, this approach holds promise not only for the development it as a novel medical diagnostic device in vitro and in vivo, but also for provision with innovative solutions to guide personalized medical care by reducing clinical costs and increasing clinical therapeutic efficacy. The latter has also a big promise to guide a drug development by pharmaceutical companies.